HTL22562 is a CGRP antagonist intended to treat acute migraines. Some prior oral CGRP antagonists failed in clinical trials due to liver tox. signals, so this program targeted a non-oral candidate with lower first-pass liver exposure that might avoid such issues. Impressively the authors were able to drive the program through structure-based [...]
< 1 minute read
Sep. 18, 2021
HTL22562: A potent, Non-oral CGRP Antagonist
HTL22562
potent, non-oral CGRP antagonist clean profile in 10-day rodent tox. from SBDD of prior ligand J. Med. Chem., Jul. 23, 2020 Sosei Heptares, Cambridge, UK
Loading...
